Literature DB >> 19797797

Metachromatic leukodystrophy: a scoring system for brain MR imaging observations.

F Eichler1, W Grodd, E Grant, M Sessa, A Biffi, A Bley, A Kohlschuetter, D J Loes, I Kraegeloh-Mann.   

Abstract

BACKGROUND AND
PURPOSE: Metachromatic leukodystrophy (MLD) is a devastating demyelinating disease for which novel therapies are being tested. We hypothesized that MR imaging of brain lesion involvement in MLD could be quantified along a scale.
MATERIALS AND METHODS: Thirty-four brain MR images in 28 patients with proved biochemical and genetic defects for MLD were reviewed: 10 patients with late infantile, 16 patients with juvenile, and 2 patients with adult MLD. All MR images were reviewed by experienced neuroradiologists and neurologists (2 readers in Germany, 2 readers in the United States) for global disease burden, as seen on the T2 and fluid-attenuated inversion recovery images. A visual scoring method was based on a point system (range, 0-34) derived from the location of white matter involvement and the presence of global atrophy, analogous to the scoring system developed for adrenoleukodystrophy. The readers were blinded to the neurologic findings.
RESULTS: Thirty-three of 34 MR images showed confluent T2 hyperintensities of white matter. The inter-rater reliability coefficient was 0.988. Scores between readers were within 2 points of each other. Serial MR imaging studies in 6 patients showed significant progressive disease in 3 patients (initial score average, 4; mean follow-up, 24.3) and no change or 1 point progression in 3 patients (initial score average, 12; mean follow-up, 12.66). Projection fibers and the cerebellum tended to be involved only in advanced stages of disease.
CONCLUSIONS: The MLD MR severity scoring method can be used to provide a measure of brain MR imaging involvement in MLD patients.

Entities:  

Mesh:

Year:  2009        PMID: 19797797      PMCID: PMC7051299          DOI: 10.3174/ajnr.A1739

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  12 in total

Review 1.  Globoid cell leukodystrophy: distinguishing early-onset from late-onset disease using a brain MR imaging scoring method.

Authors:  D J Loes; C Peters; W Krivit
Journal:  AJNR Am J Neuroradiol       Date:  1999-02       Impact factor: 3.825

2.  Late-onset metachromatic leukodystrophy clinically presenting as isolated peripheral neuropathy: compound heterozygosity for the IVS2+1G-->A mutation and a newly identified missense mutation (Thr408Ile) in a Spanish family.

Authors:  M Comabella; J S Waye; N Raguer; B Eng; C Domínguez; C Navarro; C Borrás; W Krivit; X Montalbán
Journal:  Ann Neurol       Date:  2001-07       Impact factor: 10.422

3.  MRI appearances of metachromatic leukodystrophy.

Authors:  E N Faerber; J Melvin; E M Smergel
Journal:  Pediatr Radiol       Date:  1999-09

4.  Spinal cord and cauda equina MRI findings in metachromatic leukodystrophy: case report.

Authors:  Irene Toldo; Carla Carollo; Pier Antonio Battistella; Anna Maria Laverda
Journal:  Neuroradiology       Date:  2005-07-15       Impact factor: 2.804

5.  Vanishing MS T2-bright lesions before puberty: a distinct MRI phenotype?

Authors:  D Chabas; T Castillo-Trivino; E M Mowry; J B Strober; O A Glenn; E Waubant
Journal:  Neurology       Date:  2008-09-30       Impact factor: 9.910

6.  Metachromatic leukodystrophy - mutation analysis provides further evidence of genotype-phenotype correlation.

Authors:  A Biffi; M Cesani; F Fumagalli; U Del Carro; C Baldoli; S Canale; S Gerevini; S Amadio; M Falautano; A Rovelli; G Comi; M G Roncarolo; M Sessa
Journal:  Clin Genet       Date:  2008-09-11       Impact factor: 4.438

7.  Peripheral neuropathy as the sole initial finding in three children with infantile metachromatic leukodystrophy.

Authors:  E Haberlandt; S Scholl-Bürgi; J Neuberger; S Felber; T Gotwald; R Sauter; K Rostasy; D Karall; R Korinthenberg
Journal:  Eur J Paediatr Neurol       Date:  2008-06-20       Impact factor: 3.140

8.  Adrenoleukodystrophy: a scoring method for brain MR observations.

Authors:  D J Loes; S Hite; H Moser; A E Stillman; E Shapiro; L Lockman; R E Latchaw; W Krivit
Journal:  AJNR Am J Neuroradiol       Date:  1994-10       Impact factor: 3.825

9.  Magnetic resonance imaging detection of lesion progression in adult patients with X-linked adrenoleukodystrophy.

Authors:  Florian Eichler; Asif Mahmood; Daniel Loes; Lena Bezman; Doris Lin; Hugo W Moser; Gerald V Raymond
Journal:  Arch Neurol       Date:  2007-05

10.  Alterations of brain metabolites in metachromatic leukodystrophy as detected by localized proton magnetic resonance spectroscopy in vivo.

Authors:  B Kruse; F Hanefeld; H J Christen; H Bruhn; T Michaelis; W Hänicke; J Frahm
Journal:  J Neurol       Date:  1993-12       Impact factor: 4.849

View more
  35 in total

1.  Unrelated umbilical cord blood transplant for juvenile metachromatic leukodystrophy: a 5-year follow-up in three affected siblings.

Authors:  Casey Cable; Richard S Finkel; Tanya J Lehky; Nadia M Biassou; Edythe A Wiggs; Nancy Bunin; Tyler Mark Pierson
Journal:  Mol Genet Metab       Date:  2010-10-28       Impact factor: 4.797

2.  Toward a better understanding of brain lesions during metachromatic leukodystrophy evolution.

Authors:  A Martin; C Sevin; C Lazarus; C Bellesme; P Aubourg; C Adamsbaum
Journal:  AJNR Am J Neuroradiol       Date:  2012-04-26       Impact factor: 3.825

Review 3.  Clinical neurogenetics: neuropathic lysosomal storage disorders.

Authors:  Gregory M Pastores; Gustavo H B Maegawa
Journal:  Neurol Clin       Date:  2013-11       Impact factor: 3.806

4.  Thickening of the optic nerves in metachromatic leucodystrophy: A new MRI finding.

Authors:  Dylan Roi; Kshitij Mankad; Marios Kaliakatsos; Maureen Cleary; Adnan Manzur; Felice D'Arco
Journal:  Neuroradiol J       Date:  2016-02-25

Review 5.  Posterior fossa involvement in the diagnosis of adult-onset inherited leukoencephalopathies.

Authors:  Xavier Ayrignac; Clemence Boutiere; Clarisse Carra-Dalliere; Pierre Labauge
Journal:  J Neurol       Date:  2016-04-28       Impact factor: 4.849

6.  Hereditary diffuse leukoencephalopathy with axonal spheroids (HDLS): a misdiagnosed disease entity.

Authors:  Christina Sundal; Jennifer Lash; Jan Aasly; Sarka Øygarden; Sigrun Roeber; Hans Kretzschman; James Y Garbern; Alex Tselis; Rosa Rademakers; Dennis W Dickson; Daniel Broderick; Zbigniew K Wszolek
Journal:  J Neurol Sci       Date:  2011-11-01       Impact factor: 3.181

7.  Anti-inflammatory Therapy With Simvastatin Improves Neuroinflammation and CNS Function in a Mouse Model of Metachromatic Leukodystrophy.

Authors:  Axel Stein; Stijn Stroobants; Volkmar Gieselmann; Rudi D'Hooge; Ulrich Matzner
Journal:  Mol Ther       Date:  2015-04-21       Impact factor: 11.454

8.  Complex care of individuals with multiple sulfatase deficiency: Clinical cases and consensus statement.

Authors:  Rebecca Ahrens-Nicklas; Lars Schlotawa; Andrea Ballabio; Nicola Brunetti-Pierri; Mauricio De Castro; Thomas Dierks; Florian Eichler; Can Ficicioglu; Alan Finglas; Jutta Gaertner; Brian Kirmse; Joerg Klepper; Marcus Lee; Amber Olsen; Giancarlo Parenti; Arastoo Vossough; Adeline Vanderver; Laura A Adang
Journal:  Mol Genet Metab       Date:  2018-01-31       Impact factor: 4.797

9.  MRI characteristics and scoring in HDLS due to CSF1R gene mutations.

Authors:  Christina Sundal; Jay A Van Gerpen; Alexandra M Nicholson; Christian Wider; Elizabeth A Shuster; Jan Aasly; Salvatore Spina; Bernardino Ghetti; Sigrun Roeber; James Garbern; Anne Borjesson-Hanson; Alex Tselis; Russell H Swerdlow; Bradley B Miller; Shinsuke Fujioka; Michael G Heckman; Ryan J Uitti; Keith A Josephs; Matt Baker; Oluf Andersen; Rosa Rademakers; Dennis W Dickson; Daniel Broderick; Zbigniew K Wszolek
Journal:  Neurology       Date:  2012-07-25       Impact factor: 9.910

Review 10.  In Vivo NMR Studies of the Brain with Hereditary or Acquired Metabolic Disorders.

Authors:  Erica B Sherry; Phil Lee; In-Young Choi
Journal:  Neurochem Res       Date:  2015-11-26       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.